European Antibody Congress visitor pass

FREE EXPO PASS 
31 OCT - 2 NOV


VISIT THE SHOW AND MEET WITH TECH PROVIDERS

Here is just a sample of the companies that will display new ideas and technologies in the following fields:
  • CROs:  Aquila Biomedical, Caprion Pharmaceuticals, Celerion, ...
  • CMOs:  CMC Biologics, Fujifilm Diosynth, KBI Biopharma, ...
  • Platform Technologies:  AbCheck, MaxCyte, Sartorius Stedim Biotech, ...
  • High Potency APIs:  Ezi Dok Systems, Minakem, Munit, Perkin Elmer, ...
  • Bioconjugation:  Fujifilm Diosynth, Genovis AB, Innova Biosciences,...
  • Biomanufacturing:  Acro Biosystems, Aldevron Llc, Batavia Biosciences, ...
  • Analytics:  Bio-Techne, Bruker Daltonik, Hamilton Robotics, ...
  • Identification/Validation:  Agilent Technologies, Retrogenix, ...


EXCLUSIVE : NEW 2017 SPEAKERS INCLUDE:  

 

  • Adam Levysohn at World Biosimilar Congress
    Adam Levysohn
    Head of Global Market Access Biogen Biosimilars Business Unit
    Biogen
    Silke Weber at World Biosimilar Congress
    Silke Weber
    Toxicology Project Lead
    Roche
  • Anne Cook at World Biosimilar Congress
    Anne Cook
    Biologicals Quality Assessor
    M.H.R.A.
    Marc Abromovitz at World Biosimilar Congress
    Marc Abromovitz
    Head, Industrial Hygiene
    Novartis
  • Ester Lovsin Barle at World Biosimilar Congress
    Ester Lovsin Barle
    Head of Health Hazard Assessment Center of Excellence
    Lonza
    Ber Oomen at World Biosimilar Congress
    Ber Oomen
    Executive Secretary and Treasurer
    ‎European Specialist Nurses Organisations
  • Caroline Boulliat at World Biosimilar Congress
    Caroline Boulliat
    Immunology, Oncology. Biosimilar Business Unit Head
    Amgen Europe Gmbh
    Ulf Johansson at World Biosimilar Congress
    Ulf Johansson
    Project Manager
    AstraZeneca
  • Jeff Parry at World Biosimilar Congress
    Jeff Parry
    Senior Scientist Manufacturability
    AstraZeneca
    Dan Cimpoeru at World Biosimilar Congress
    Dan Cimpoeru
    Board Member
    European Cancer Patient Coalition
  • Elena Wolff-Holz at World Biosimilar Congress
    Elena Wolff-Holz
    Elena Wolff-Holz, Chair, Biosimilar Medicinal Products Working Party (BMWP)
    Paul Ehrlich Institut
    Olindo Lazzaro at World Biosimilar Congress
    Olindo Lazzaro
    Director, Environment, Health & Safety
    AbbVie
  • Dr Ulrich Brinkmann at World Biosimilar Congress
    Dr Ulrich Brinkmann
    Scientific Director, Expert Scientist
    Roche
    Ildiko Ziegler at World Biosimilar Congress
    Ildiko Ziegler
    Distinguished Validation Expert
    Gedeon Richter Plc
  • Karoline Bechtold Peters at World Biosimilar Congress
    Karoline Bechtold Peters
    Senior Strategy & Technology Leader - Pharmaceutical Development
    F. Hoffmann-La Roche Ltd
    Francois Xavier Frapaise MD at World Biosimilar Congress
    Francois Xavier Frapaise MD
    CMO
    Merck Biosimilars
  • Ian Henshaw at World Biosimilar Congress
    Ian Henshaw
    Head of Business Operations
    Biogen
    Claudia Sehner at World Biosimilar Congress
    Claudia Sehner
    Principal Scientist Toxicology
    Boehringer Ingelheim Pharma GmbH & Co. KG
  • Ingrid Schwarzenberger at World Biosimilar Congress
    Ingrid Schwarzenberger
    Head of Global Regulatory Affairs Biopharmaceuticals
    Sandoz Biopharmaceuticals Gmbh
    Reinhold Maeck at World Biosimilar Congress
    Reinhold Maeck
    Head of Corporation EH&S Regulatory Intelligence
    Boeringer Ingelheim
  • Margaret Dolan at World Biosimilar Congress
    Margaret Dolan
    Regional Pharmacy Procurement Specialist
    N.H.S.
    Dr John Delaney at World Biosimilar Congress
    Dr John Delaney
    Executive Director, Amgen Biologics Discovery
    Amgen
  • Dr Michael DeRidder at World Biosimilar Congress
    Dr Michael DeRidder
    Senior Director, Early Pipeline Commercial Strategy for Oncology Cell Therapy, Neuroscience, and ADD
    GSK
    Dr Peter Ellmark at World Biosimilar Congress
    Dr Peter Ellmark
    Principal Scientist, Immuno-oncology
    Alligator Bioscience Ab
  • Dr M. Anthony Moody at World Biosimilar Congress
    Dr M. Anthony Moody
    Associate Professor of Paediatrics, Assistant Professor of Immunology
    Duke University Medical Center
    Prof. Andreas Plueckthun at World Biosimilar Congress
    Prof. Andreas Plueckthun
    Professor of Biochemistry, Director, Department of Biochemistry
    University of Zurich, Dept. of Biochemistry
  • Dr Janice Reichert at World Biosimilar Congress
    Dr Janice Reichert
    Executive Director
    The Antibody Society
    Dr Christian Rommel at World Biosimilar Congress
    Dr Christian Rommel
    Global Head of Oncology Discovery
    F Hoffman La Roche Ltd
  • Dr Jerald Sadoff at World Biosimilar Congress
    Dr Jerald Sadoff
    Senior Advisor Vaccine Development
    Janssen Infectious Diseases and Vaccines
    Dr Puja Sapra at World Biosimilar Congress
    Dr Puja Sapra
    Vice President and Chief Scientific Officer, Targeted Therapeutics Discovery, Oncology R&D
    Pfizer Biotherapeutics
  • Joern Schmitz at World Biosimilar Congress
    Joern Schmitz
    Department Head
    Fraunhofer I.M.E.
    Dr Michael Streit at World Biosimilar Congress
    Dr Michael Streit
    Sr Director Clinical Research Lead
    Janssen
  • Dr Alain Vertes at World Biosimilar Congress
    Dr Alain Vertes
    Managing Director
    NxR Biotechnologies
    Sir Gregory Winter at World Biosimilar Congress
    Sir Gregory Winter
    Master, Trinity College Cambridge
    University of Cambridge
  • Dr Jens Würthner at World Biosimilar Congress
    Dr Jens Würthner
    Head of Clinical Development – EU
    ADC Therapeutics

 

THE OPPORTUNITY

65

SPEAKERS

25

BIOSIMILAR DEVELOPERS SPEAKING AT THE EVENT

200

DELEGATES

 

2

TRACKS OF CONTENT OVER 2 DAYS

4

COLOCATED EVENTS

600

ATTENDEES FROM PHARMA BIOTECH & HEALTHCARE

 

ADVISORY BOARD

Uwe Gudat

Uwe Gudat 
Head of Safety, Biosimilars 

Merck

Alain Beck

Alain Beck 
Senior Director Analytical Chemistry, CIPF and Associate Editor 

mAbs 

Paul Chrisp

Paul Chrisp 
Programme Director, Medicines and Prescribing Center 

NICE

Gianluca Trifirò

Gianluca Trifirò 
Assistant Professor of Pharmacology 

Erasmus Medical Center

 

 Cecil Nick

Cecil Nick
Vice President, Biotechnology
PAREXEL

Steinar Madsen

Steinar Madsen 
Medical Director, Department of Drug Information, Norwegian Medicines Agency

Ingrid Schwarzenberger

Ingrid Schwarzenberger,  Head Global Regulatory Affairs, Sandoz Biopharmaceuticals

adam levysohn

Adam Levysohn , Head of Global Market Access Biogen Biosimilars Business Unit, Biogen

 

DOWNLOAD THE BROCHURE

WHAT IS THE WORLD BIOSIMILAR CONGRESS?

 

CONFERENCE

NETWORKING 

Biosimilar 2016 panel discussion

The World Biosimilar Congress is a commercially focused event bringing together the full value chain and located in one of the world’s major life science hubs, Basel. Consisting of thought-leaders from across the globe, the World Biosimilar Congress looks at commercialising and pushing forward the adoption of biosimilars globally. Over the last 5 years, the Congress has built up a reputation for delivering high level content and bringing together the senior executives from sourcing through to patient. It is co-located with the European Antibody Congress, World Immunotherapy Congress, and HPAPI World Congress.

Biosimilar 2016 panel discussion

The World Biosimilar Congress recognises the importance of networking and offers an experience which allows you to do just that. With a series of round table discussions, speed networking, networking drinks receptions, breaks and lunches, we provide you with plenty of opportunities to have those all important conversations. With multiple networking formats we enable you to have casual chats and introductions without compromising your time attending the conference sessions.

 

DOWNLOAD THE BROCHURE

TRACK 1 

* New* Track 1: Market access strategies, opportunities and commercial challenges 

  • Updates on biosimilar and biobetter regulatory guidelines

  • Streamlining approval and access for follow-on biologics

  • Opportunities and challenges in bringing future  biosimilars to market

  • Emerging markets and the establishment of biosimilar products

  • Technology transfer strategies for market access

  • Successful biosimilar product case studies from benchtop to market

TRACK 2

Track 2: Biosimilar and Biobetter development 

  • Biosimilar and biobetter development and clinical case studies

  • Designing and conducting global clinical trials

  • Designing clinical models and using data to effectively demonstrate biosimilarity

  • Opportunities in biobetters development

  • The latest on demonstrating interchangeability

  • Approaches to harmonizing immunogenicity testing

  • Novel techniques and technologies for characterisation, assay development and extrapolation

  • *New* Pharmacovigilence (side effects) and innovative clinical trials 

 

bioismilar prospectus 2017

 


PUT YOUR COMPANY AT THE FOREFRONT OF THE BIOSIMILAR INDUSTRY

 

Download the prospectus to find out different ways you can get involved in the most important biosimilar meeting in europe.

 

DOWNLOAD PROSPECTUS

 

"This is an excellent strategic conference on the global development of biosimilars and should be attended by anyone developing biosimilars."


N.D.A. Regulatory Science Ltd

col-md-1

WHO ATTENDS?

 

Bayer Pharma AG G.E Helthcare Janssen Takeda Express Scripts Inc Merck Bio Rad Laboratories Cellitron Terumo  Europa Bioproducts Amgen Sandoz Biogen PAREXEL Merck Millipore Boehringer Ingelheim Abbvie Ag Quintiles  Alexion Pharma Pfizer Roche Myoderm Fujifilm Kyowa Kirin Biologics Alliance for Safe Biologic Medicines NDA Group Sterne Kessler Goldstein And Fox Plc Prozyme  Cinfa Biotech  ExcellGene Orion Pharma Altran Deallus  Prozyme   A.L.S. Automated Lab Solutions Resindion srl McKinsey & Company Genzyme IMS Health MSPharma Daiichi Sankyo INC Research Hospira R-Pharm ProBioGen  Novo Nordisk Pharmatech Bionical Ltd Alvotech Wyatt Health Management Promogen-MAB BioXpress Therapeutics Dr. Reddy's Laboratories SA University of Oslo  Asterand Avrentim Johnson and Johnson Probiomed  Vantage Health Hoffman La Roche  Probiomed  MedImmune InSight Biopharmaceuticals

col-md

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Partner with the world biosimilar congress:

Forge new partnerships

generate new leads

build your brand presence

 

DOWNLOAD PROSPECTUS

"Great conference. Great planning, execution and very responsive throughout the process."

 

Executive Director - Global Colon Cancer Association

 

bioismilar prospectus 2017

 

TECHNICAL SEMINAR BY BRUKER DALTRONIK

 

Discover how to overcome the Challenges of Intact Biotherapeutics Characterization with Ultra-High Resolution Mass Spectrometers and the Latest in Automated Biopharmaceutical Software Package – Biopharma Compass 2.0

 

READ MORE